Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

INBX

Inhibrx Biosciences (INBX)

Inhibrx Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:INBX
DateTimeSourceHeadlineSymbolCompany
10/24/20224:37PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INBXInhibrx Biosciences Inc
10/20/20224:05PMPR Newswire (US)Inhibrx Announces Participation in Upcoming Scientific ConferencesNASDAQ:INBXInhibrx Biosciences Inc
10/18/20224:38PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INBXInhibrx Biosciences Inc
10/13/20228:37AMTipRanksThis Insider Bought Inhibrx (NASDAQ: INBX) Stock Worth $40MNASDAQ:INBXInhibrx Biosciences Inc
10/05/20224:16PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INBXInhibrx Biosciences Inc
10/05/202212:15AMTipRanksInhibrx (INBX) Receives a Buy from JMP SecuritiesNASDAQ:INBXInhibrx Biosciences Inc
10/04/202212:46PMDow Jones NewsInhibrx Shares Rise 33% After FDA Talks on INBRX-101NASDAQ:INBXInhibrx Biosciences Inc
10/04/202211:15AMTipRanksInhibrx Jumps After Possibility of FDA Approval for INBRX-101NASDAQ:INBXInhibrx Biosciences Inc
10/04/20229:54AMDow Jones NewsInhibrx Shares Jump Premarket After Talks With FDA on INBRX-101NASDAQ:INBXInhibrx Biosciences Inc
10/04/20228:03AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:INBXInhibrx Biosciences Inc
10/04/20228:00AMPR Newswire (US)Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 StudyNASDAQ:INBXInhibrx Biosciences Inc
10/03/20224:30PMPR Newswire (US)Inhibrx To Host Webcast to Announce Regulatory Pathway for INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin DeficiencyNASDAQ:INBXInhibrx Biosciences Inc
09/14/20224:11PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INBXInhibrx Biosciences Inc
09/07/20224:58PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INBXInhibrx Biosciences Inc
08/25/20224:21PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INBXInhibrx Biosciences Inc
08/15/20224:12PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:INBXInhibrx Biosciences Inc
08/15/20224:05PMPR Newswire (US)European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of ChondrosarcomaNASDAQ:INBXInhibrx Biosciences Inc
08/11/20225:15PMTipRanksInhibrx (INBX) Receives a Buy from JMP SecuritiesNASDAQ:INBXInhibrx Biosciences Inc
08/10/20224:09PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:INBXInhibrx Biosciences Inc
08/08/20225:19PMPR Newswire (US)Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate HighlightsNASDAQ:INBXInhibrx Biosciences Inc
08/08/20224:22PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INBXInhibrx Biosciences Inc
08/08/20224:20PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:INBXInhibrx Biosciences Inc
08/08/20224:18PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:INBXInhibrx Biosciences Inc
08/04/20224:34PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INBXInhibrx Biosciences Inc
07/19/20226:02AMEdgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:INBXInhibrx Biosciences Inc
07/08/20224:03PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INBXInhibrx Biosciences Inc
07/06/202212:36AMTipRanksJMP Securities Thinks Inhibrx’s Stock is Going to RecoverNASDAQ:INBXInhibrx Biosciences Inc
06/30/20229:04AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:INBXInhibrx Biosciences Inc
06/30/20229:00AMPR Newswire (US)Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional $60 Million from Oxford FinanceNASDAQ:INBXInhibrx Biosciences Inc
06/06/202212:25AMTipRanksJMP Securities Sticks to Its Buy Rating for Inhibrx (INBX)NASDAQ:INBXInhibrx Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:INBX

Your Recent History

Delayed Upgrade Clock